Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Testosterone gel dosing in depression with hypogonadism
IRCT20191211045698N1Phase 2Completed
- Sponsor
- Tehran University of Medical Sciences
- Start
- Apr 2019
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, randomised, single-blind trial of testosterone in major depressive disorder (MDD) and Hypoandrogenism (TD) (2 arms), sponsored by Tehran University of Medical Sciences. Primary endpoints: Hamilton score and Testosterone level. Started Apr 2019; status: completed.
02
Drugs
testosterone
03
Conditions
major depressive disorder (MDD)Hypoandrogenism (TD)
Beyond the preview
Go deeper on IRCT20191211045698N1.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on IRCT20191211045698N1.